- ImmuCell Corp., of Portland, Maine, received a $507,000 Phase IISmall Business Innovation Research grant from the National Instituteof Allergy and Infectious Diseases. The funding will be used to supportdevelopment of a passive antibody product for the treatment ofcrytosopridiosis in AIDS patients.- Cypros Pharmaceutical Corp., of Carlsbad, Calif., received a$460,000, two-year Phase II Small Business Innovation Research grantfrom the National Institutes of Health for funding the development ofneuronal calcium channel-blocking drugs for treating neurologic andpsychiatric diseases.- Unigene Laboratories Inc., of Fairfield, N.J., is extending theexpiration date of its class B warrants by one year, to Aug. 11, 1995. Aclass B warrant is exercisable at $5 for one share of common stock.- Mediscience Technology Corp., of Cherry Hill, N.J. completed theprivate placement of Phase I of its $4 million to $6 million financingpackage for more than $1 million, which was coordinated by CobyCapital Corp. The company said completion of Phase II of theplacement will allow NASDAQ listing for Mediscience.
(c) 1997 American Health Consultants. All rights reserved.